Reinventing Skin Science

Presentations & Publications

 

January 17-22, 2020 – Winter Clinical Dermatology Symposium


Safety and Efficacy of VP-102 in Molluscum Contagiosum (MC) by Lesion Count Quartile: Pooled Results of Two Phase 3 Multicenter, Randomized, Vehicle-Controlled Trials for the Topical Treatment of

 

October 17-20, 2019 – Fall Clinical Dermatology Symposium



Pooled Results of Two Phase III Multicenter, Randomized, Vehicle-controlled Trials Using a Novel Drug Delivery-device Combination Formulation of 0.7% (w/v) Cantharidin (VP-102) for the Topical Treatment of Molluscum Contagiosum (CAMP-1 and -2)


Pooled Results of Two, Phase III Studies With VP-102 for the Topical Treatment of Molluscum Contagiosum: ≥75% and ≥90% Clearance Rates for Treated Lesions in CAMP-1 and CAMP-2

 

October 3, 2019 – Integrative Dermatology Symposium (Poster)



CAMP-1 and CAMP-2: Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Pivotal Studies Investigating VP-102, a Novel Drug-Device Combination Containing a Topical Formulation of Cantharidin for the Treatment of Molluscum Contagiosum

 

July 12, 2019 – Society of Pediatric Dermatology (Posters)


CAMP-1 and CAMP-2: Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Pivotal Studies Investigating VP-102, a Novel Drug-Device Combination Containing a Topical Formulation of Cantharidin for the Treatment of Molluscum Contagiosum
 
INNOVATE: A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy, and Systemic Exposure of VP-102 Topical Film-Forming Solution [0.7% (w/v) cantharidin] in Subjects (2 years and older) with Molluscum Contagiosum